Phase 3 Readout

KYTX: Phase 3 Topline: KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous

Name: Phase 3 Topline: KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous
Start: 2028-09-01
End: 2028-09-01

September 1, 2028 · kyv-101. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: September 1, 2028
Company: Kyverna Therapeutics, Inc. (KYTX)
Drug: kyv-101

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous

September 1, 2028

KYTX overview →

Company: Kyverna Therapeutics, Inc. (KYTX)
Drug: kyv-101
Indication: Generalized Myasthenia Gravis; Myasthenia Gravis